Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 11/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5813871 | 0.96 | MEN1 (0.46) | MEN1KMT2APRKCITSHRCHRM4 | |
| SCHEMBL5130858 | 0.93 | PRKCI (0.47) | MEN1KMT2APRKCICHRM4 | |
| SCHEMBL5121900 | 0.90 | PRKCI (0.60) | MEN1KMT2APRKCITNFNOD1 | |
| SCHEMBL5129098 | 0.89 | ALDH1A1 (0.49) | MEN1KMT2ATSHR | |
| SCHEMBL8170980 | 0.87 | KMT2A (0.46) | MEN1KMT2ATSHRCHRM4TNF | |
| SCHEMBL8170575 | 0.87 | KMT2A (0.48) | MEN1KMT2ATSHRCHRM4BCHE | |
| SCHEMBL5129890 | 0.86 | PRKCI (0.51) | PRKCI | |
| SCHEMBL7172866 | 0.86 | ALDH1A1 (0.52) | MEN1KMT2ATSHR | |
| SCHEMBL5121765 | 0.86 | PRKCI (0.57) | MEN1KMT2APRKCICHRM4 | |
| SCHEMBL5123241 | 0.85 | CHRM4 (0.42) | MEN1KMT2ATSHRCHRM4TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | MEN1 696/4885KMT2A 388/4885PRKCI 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.